Pregnancy is possible in hepatitis B patients, with emphasis on effective interruption of vertical transmission from mother to child. Pregnancy can increase the burden on the liver, so it is best not to get pregnant when the liver function is not normal during the inflammatory phase of hepatitis B, and attention should be paid to contraception. If the liver function is normal, it is possible to have a healthy baby when the mother is physically and mentally well after the HbeAg has turned negative. Pregnant women are advised to take 200 units of Hepatitis B highly effective immunoglobulin every month during the 7th, 8th and 9th trimesters of pregnancy to prevent intrauterine infection of Hepatitis B. After birth, the child should receive the first injection of 100 IU of hepatitis B HVP immunoglobulin and 30 micrograms of hepatitis B vaccine subcutaneously within 24 hours, and 30 micrograms of hepatitis B vaccine in the first and sixth months. Pregnant women with hepatitis B who develop serious abnormalities in liver function during pregnancy, such as a rapid rise in transaminases and bilirubin, should terminate the pregnancy promptly. Recently, it has been reported that the oral antiviral drug tebivudine, which is started after about 6 months of pregnancy, is less effective in reducing the infection in the child than if it is not used in HBVDNA-positive pregnant women. As for the ability to breastfeed after birth, it depends on the results of the mother’s serum hepatitis B virus marker test. A mother who is positive for HBsAg alone and negative for both HbeAg and HBVDNA can breastfeed. Newborns are vaccinated against hepatitis B according to the 0-1-6 schedule. If the mother is not only HBsAg positive but also HbeAg and N or HBVDNA positive, if she wants to breastfeed herself, she should add 200 units of high potency immunoglobulin within 24 hours after birth in addition to hepatitis B vaccination as scheduled, which can reduce mother-to-child transmission. The aim of antiviral treatment after pregnancy for hepatitis B patients is to treat hepatitis in pregnant women and to interrupt mother-to-child transmission of HBV. The majority of pregnant women do not require treatment because of the mild inflammation, poor efficacy, and impact on the fetus; however, treatment is still needed to reduce mortality when HBV infection and liver function deteriorate; target selection: high viral load of 105 cps; low viral load but with a history of mother-to-child transmission. Drug selection: Class A: none; Class B: tenofovir , telbivudine; Class C: lamivudine, adefovir, entecavir, interferon (lamivudine is the most used, only lamivudine has a safety record). Timing of dosing: start in the last 3 months of pregnancy (28-32 weeks); full treatment is not recommended: minimize fetal exposure to drugs; it is sufficient to reduce HBV DNA levels to a certain level before delivery; even with full antiviral, serologic conversion of HBeAg may not be achieved; long-term application of lamivudine occurs as a mutation of the virus, leading to antiviral failure; only the second 3 months of pregnancy Safety record of use . When to discontinue: Continuous treatment after delivery for those on full treatment; discontinuation 2-3 months after delivery for those on MTCT only, but with regular observation. Precautions: selection of the target group; adequate communication with the pregnant woman; communication of the purpose and possible risks; use of relatively safe drugs; generally not for the whole course of treatment; observation after discontinuation of the drug.